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Abstract: Molecular diagnostics is broadly available in clinical microbiology laboratories worldwide, especially for the 
detection and identification of difficult-to-cultivate microorganisms. The field of clinical microbiology has experienced 
significant changes over the past decade due to extensive molecular biology research that resulted in novel molecular 
diagnostics technologies. These new technologies are being introduced in clinical microbiology laboratories with the 
aim of improving sensitivity, specificity, accuracy and time-to-diagnosis, ensuring valuable data for effective infectious 
disease clinical management, infection control and surveillance. They have a potential to greatly improve general 
healthcare, but also present certain challenges, mainly regarding the cost and the proper definition of test ordering and 
interpretation. This review will discuss the current and potential application of next-generation sequencing, digital PCR 
and syndromic multiplex molecular assays in clinical microbiology. 
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Clinical microbiology laboratories routinely detect and 
identify medically important microorganisms in order 
to manage clinical decisions as well as to monitor the 
spread of infectious diseases and antimicrobial 
resistance. The information obtained from a clinical 
microbiology laboratory is extremely valuable for 
proper patient management and infection monitoring 
and control. Therefore, the laboratory’s priority is to 
produce results in a timely, sensitive and precise 
manner. Routine work in clinical microbiological 
laboratories traditionally includes the examination of 
phenotypic characteristics of microorganism cultures 
grown in ideal growth conditions. This approach is 
extensively being used in laboratories worldwide and is 
often supported by semiautomatic and automatic 
methods. However, this approach is still limited by its 
inability to fully characterize all the medically relevant 
microorganisms and to provide results in an 
appropriate time interval for clinical management. 
The last two decades have been characterized by the 
rapid development of all aspects of technology, which 
has also reflected on significant developments in the 
field of molecular biology and biotechnology. New 
molecular biology techniques have become the basis 
for the development of various clinical microbiology 
laboratory techniques that allow a significant departure 
from the above-mentioned traditional techniques. New 
molecular microbiology diagnostic methods enable 
rapid, highly specific and sensitive microbiological 
diagnostics and present a major clinical advantage 
providing more complex and complete clinical 
information than classic methods.  
Next-generation sequencing, digital PCR and 
syndromic multiplex molecular assays are modern 
methods in clinical microbiology laboratories that 
provide invaluable information that is directly usable in 
both patient management (such as timely and accurate 
diagnosis and administration of highly specific 
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antimicrobial drugs) and public health microbiology 
(such as antimicrobial resistance monitoring and 
control and infectious diseases outbreak 
investigations). This review will explore the current 
application of these methods and their potential for 
inclusion in the routine work of the clinical 




Next-generation sequencing applications in clinical 
microbiology 
Next-generation sequencing (NGS) represents 
technologically diverse methods that allow 
simultaneous and independent sequencing of a large 
number of DNA fragments. These technologies enable 
researchers to produce an enormous volume of 
sequencing data in a short period of time and at a 
relatively low cost, making them a useful clinical tool. 
NGS has successfully been used in clinical 
microbiology for a variety of applications, like whole 
genome sequencing (WGS) and metagenomic NGS.  
Current applications of WGS include microorganism 
typing, epidemiology and outbreak investigations, 
antimicrobial susceptibility predictions and virulence 
factor determination. Metagenomic NGS, on the other 
hand, focuses on the identification of pathogens 
directly from clinical samples. This approach is very 
complex due to the polymicrobial sample content, but 
gives highly valuable information regarding the 
microorganism diversity of the sample. 
 
 
WGS in epidemiology and outbreak management 
Various evolutionary studies used NGS to examine the 
origin and spread of bacterial pathogens at a global 
level. Even though some of these evolutionary studies 
were exclusively research-oriented, their impact on 
clinical microbiology is crucial because they set the 
ground for clinical sequencing and generating reference 
genome databases. Several studies analyzed the 
epidemiology and global spread of various methicillin-
resistant S. aureus (MRSA) strains. Harris et al.1 used a 
high-throughput genomics approach to get a high-
resolution insight into the epidemiology and 
microevolution of one of the widely disseminated 
MRSA clonal lineages, sequence type 239 (ST239).  
McAdam et al.2 investigated the evolution and 
transmission patterns of a pandemic MRSA clone 
(ST36-II), collected from patients on three continents 
over a 53-year period. Authors used a high-resolution 
phylogenomic approach that provided them with an 
understanding of the emergence, transmission and 
hospital adaptation of a major MRSA clone. Monecke 
et al.3 performed molecular typing of a pandemic 
MRSA strain (ST-239-MRSA-III) and investigated its 
intercontinental spread with the use of DNA 
microarrays and whole-genome sequencing. He et al.4 
used whole-genome sequencing and phylogenetic 
analysis for the investigation of the evolution and 
global spread of an epidemic Clostridium difficile 
strain (027/BI/NAP1). In their research, the authors 
managed to identify key genetic elements that enabled 
the rapid dissemination and spread of this epidemic 
strain through the global healthcare system. A study of 
Mutreja et al.5 identified the phylogeny of the lineage 
responsible for the current cholera pandemic. The 
authors identified high-resolution genetic markers in a 
number of whole-genome sequences of Vibrio cholerae 
isolates and managed to explain the origin and 
transmission events that shaped the current pandemic.  
Another WGS application comes from the field of 
public health microbiology and includes the 
investigation of outbreaks of pathogenic 
microorganisms both in hospital and community 
settings.  Several retrospectively conducted studies 
used whole-genome sequencing data to determine 
outbreak patterns of infections caused by E. coli,6 M. 
tuberculosis,7 Acinetobacter baumannii8 and the 
measles virus.9 These studies had no impact on 
immediate clinical decisions; however, they 
demonstrated the valuable potential of using WGS in 
outbreak investigations. Studies that investigated 
outbreak events in real-time10–12 provided detailed 
information in a clinically relevant time, which helped 
with the clinical management of outbreaks. These 
studies confirmed that WGS has great potential for 
enabling clinicians to take appropriate infection control 
and public health measures in a timely manner, thus 
reducing the impact of outbreak.  
When considering the results of the aforementioned 
studies, one has to agree that whole-genome 
sequencing is a superior technique over the bacterial 
genotyping techniques that investigate only certain 
regions of the microbial genome and are historically 
used in microbial epidemiology studies and outbreak 
management. Particularly interesting is the ability to 
obtain information on microorganism transfer between 
health centers and even individual patients within the 
same healthcare facility. The amount and quality of 
information obtained by WGS goes beyond previously 
used techniques, although it is still uncertain when 
WGS will be introduced into the routine work of the 
clinical microbiology laboratory. The price of the 
methodology is one of its disadvantages, but there are 
other considerations like turnaround time, sequencing 
sensitivity, personnel requirements and tight quality 
control, that need to be addressed prior to WGS 
introduction into the routine laboratory workflow. 
 
 
Antimicrobial susceptibility testing 
A very exciting possibility of WGS application in 
clinical microbiology is the determination of 
antimicrobial susceptibility based on the identification 
of genes and/or chromosomal mutations that harbor 
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antimicrobial resistance. This methodology has the 
potential to significantly reduce the time to optimal 
antimicrobial therapy compared to conventional 
antimicrobial susceptibility testing (AST). Several 
studies published in recent years successfully used 
WGS for the determination of antimicrobial 
susceptibility of various pathogens such as 
Staphylococcus aureus,13 Mycobacterium 
tuberculosis,14 Escherichia coli,15 Neisseria 
gonorrhoeae,16 Klebsiella pneumoniae.17 One recent 
study by Nguyen et al.18 is of particular interest. The 
authors of this study used whole genome sequencing 
data together with paired antimicrobial susceptibility 
data of more than five thousand nontyphoidal 
Salmonella strains to generate a learning model for 
predicting minimum inhibitory concentration (MICs) 
for 15 antibiotics. This study is, to date, one of the 
largest published MIC modelling studies and bears a 
strategy for developing whole genome sequence-based 
models for surveillance and clinical diagnostics that 
have a high potential of application to other important 
human pathogens.  
It is not very likely that complete replacement of 
routine phenotypic testing with WGS will be possible 
in the very near future; however, this new methodology 
does hold huge potential and it is a matter of time 
before the current limitations are overcome. 
Specifically, several issues need to be addressed in 
order for new technology to replace existing ones. 
Although the cost of sequencing has been significantly 
decreasing over time, the overall cost of setting up a 
sequencing laboratory is still a major obstacle for many 
laboratories. Furthermore, when looking from an expert 
perspective, a number of problems need to be solved in 
order to provide accurate, reliable, and clinically 
relevant antimicrobial susceptibility information from 
WGS data. Current antimicrobial resistance gene 
databases are very informative, but lack standardization 
and timely updating, which makes them insufficient for 
routine use in the prediction of antimicrobial 
susceptibility from whole genome sequencing data. In 
addition, complex mechanisms of antimicrobial 
resistance are multivariate, and often include multigene 
parameters, and/or different levels of transcription of 
individual resistance genes that determine the particular 
phenotype of antimicrobial resistance, which is 
difficult to recognize from the genome sequence alone. 
The development of machine learning algorithms that 
could accurately predict a clinically acceptable 
antimicrobial phenotype from an isolated genomic 
sequence, and which would be suitable for all clinically 
relevant microorganisms, could ultimately allow a 
complete transition from phenotypic testing to the 
determination of antimicrobial resistance via WGS. 
 
 
Metagenomic NGS in clinical microbiology 
Metagenomic NGS (mNGS) can be used in both 
untargeted and targeted approaches. In untargeted 
approaches, mNGS enables the characterization of all 
DNA or RNA found in a clinical specimen and 
represents an essentially hypothesis-free diagnostic 
approach regarding the causative agent of infection. 
Targeted mNGS uses specific PCR primers to enrich 
individual genes or genomic regions, which in turn 
increases the sensitivity for the detection of specific 
microorganisms, but decreases the potential to detect 
all microorganisms present in the clinical sample. 
Some of the major disadvantages of this method 
include high overall cost of test performance, 
questionable sensitivity due to the high host to 
pathogen nucleic acid ratio, the need for specific 
personnel not available to each laboratory and quality 
control concerns. However, some laboratories have 
been able to overcome many of the issues mentioned 
and successfully validated mNGS for the diagnosis of 
infectious diseases, such as sepsis19 and 
meningitis/encephalitis,20 demonstrating that the new 
methodology certainly has great potential for the use in 
clinical microbiology laboratories in the future. 
 
 
Digital PCR - application for clinical microbiology 
The term “digital” PCR was first used in the 1999 
report by Vogelstein and Kinzler.21 This method was, 
however, not new, as it had been established during the 
previous decade, and was known under the terms 
“single molecule PCR” or “limiting dilution PCR”.22 
Digital PCR (dPCR) is a method that determines the 
absolute concentration of nucleic acids, without the 
need for an external standard curve. In addition, it is 
more precise, more accurate in the presence of PCR 
inhibitors and offers more accurate quantitation in low 
amplification efficiency conditions when compared to 
quantitative PCR (qPCR). For all the reasons 
mentioned, dPCR has had various applications since its 
introduction, primarily in the fields of human genetics 
and oncology.  
In the clinical microbiology setting, dPCR has several 
potential applications in the fields of virology, 
bacteriology and parasitology. There are several 
advantages of dPCR over more commonly used qPCR. 
One of them is the ability for the quantitation of 
pathogens that do not have well-characterized reference 
materials available. In addition, as dPCR if less 
affected by sequence variation, it is more appropriate 
for DNA quantitation than qPCR, when materials used 
for the standard curve and the sample show slight 
sequence diversity, as shown by Sedlak et al.23 The 
authors of this study compared the accuracies of 
reverse transcription-quantitative PCR (RT-qPCR) and 
reverse transcription-digital PCR (RT-dPCR) for 
quantifying human rhinoviruses (HRV) RNA. Their 
results suggest that RT-dPCR is a method of choice for 
HRV quantification studies, as it more accurately 
quantified HRV RNAs across genotype groups that had 
up to two target-sequence mismatches within the 
primer or probe binding region. 
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Absolute quantitation of pathogen DNA performed by 
dPCR offers significant advantages over qPCR, as 
shown in several virus quantitation studies (CMV 
absolute quantitation,24, 25 hepatitis E virus (HEV) RNA 
quantification,26 hepatitis B virus DNA 
quantification,27 HIV-2 plasma RNA quantification,28 
cell-associated HIV-1 RNA quantitation29). Due to the 
increased sensitivity over qPCR, dPCR may offer some 
novel applications, like detecting circulating human 
papillomavirus (HPV) DNA in patients with HPV-
associated carcinomas. A study by Jeannot et al.30 
showed that in 87% of patients with invasive 
carcinoma (93% when using more optimally stored 
serum samples) HPV DNA was detected and quantified 
using digital droplet PCR (ddPCR, a variant of dPCR). 
DNA levels in cervical cancer patients were related to 
the clinical stage and the size of the tumor.  
Besides virology, dPCR quantification assays can be 
used in other parts of the clinical microbiology 
laboratory, like parasitology and bacteriology. Two 
recent studies used ddPCR for sensitive and accurate 
quantification of human malaria parasites. Koepfli et 
al.31 accurately diagnosed and quantified Plasmodium 
falciparum and Plasmodium vivax in clinical patients 
across parasite densities commonly observed in human 
blood. In addition, they showed that for low-density 
infections, quantification of malaria parasites by 
ddPCR yields more precise results than qPCR. 
Srisutham et al.32 developed a new sensitive ddPCR 
assay for the detection and quantification of four 
human Plasmodium species.  
In the field of bacteriology, digital PCR was recently 
used for the detection of Mycobacterium tuberculosis 
DNA from whole blood of patients with pulmonary and 
extrapulmonary tuberculosis in a study by Yang et al.33 
The authors of the study compared ddPCR and qPCR 
for detecting low levels of circulating Mycobacterium 
tuberculosis DNA. Their results showed an increased 
sensitivity for the detection of M. tuberculosis DNA 
with ddPCR over qPCR and concluded that ddPCR 
might potentially be used as a non-invasive, rapid and 
highly sensitive diagnostics tool for the detection of 
both pulmonary and extrapulmonary tuberculosis. In 
another study by King et al.34 the authors used ddPCR 
for the detection and absolute quantification of 
Borrelia burgdorferi DNA in adult patients and Ixodes 
scapularis ticks. They concluded that ddPCR was as 
sensitive as a qPCR assay, but had some advantages 
over it, like fewer overall reactions and decreased 
sensitivity to PCR inhibitors. 
The results of these studies suggest that dPCR might 
replace qPCR in a variety of clinical microbiology 
applications with respect to purpose, target 
microorganism and sample type. It is presumable that 
this methodology will be more readily used in clinical 
microbiology laboratories, especially after the 
optimization of several key factors such as test 
performance cost, laboratory workflow and quality 
control. 
Syndromic panel-based testing of bloodstream 
infections 
There are several US Food and Drug Administration 
(FDA) approved/cleared syndromic multiplex assays 
for rapid microbiology testing of positive blood culture 
bottles. Sepsis is considered a major cause of morbidity 
and mortality and also poses a healthcare economic 
burden, thus there is a great need to rapidly and 
accurately diagnose microorganisms that cause it.35   
A number of clinical evaluation studies examined the 
characteristics of syndromic panel-based assays for 
rapid microbiology testing of bloodstream infections 
and their impact on clinical management. A 
retrospective study conducted by Ward et al.36 tested 
two FDA-approved panel-based assays for the 
identification of both Gram-positive and Gram-
negative bacteria and compared their accuracy, 
turnaround time for organism and resistance gene 
identification to standard clinical microbiology culture-
based methods. Their results showed that both panels 
provided accurate results significantly faster than 
standard microbiology methods. However, in their 
setting, the earlier result had a modest impact upon 
clinical management. In the author’s opinion, panel-
based assays cannot be used as standalone tests, but 
rather as an add-on to conventional methods, due to 
their limitations in the choice of microorganisms and 
antimicrobial resistance genes as assay targets.  
A study conducted by Mestas et al.37 evaluated the use 
of a panel-based assay that identifies 12 Gram-positive 
organisms and three respective resistance markers for 
the diagnosis of bloodstream infections in pediatric 
population in a setting where the assay was performed 
24 hours a day, seven days a week. The authors 
observed a dramatic improvement of the turnaround 
time, especially for the identification of methicillin-
resistant S. aureus (MRSA) and vancomycin-resistant 
Enterococci (VRE).  
A study by Ledeboer et al.38 examined the use of a 
panel-based assays that detect eight genus or species 
targets (all Gram-negative) and six resistance 
determinants on a large number of samples (1847 in 
total). This study demonstrated high positive, PPA, 
(97.9%) and negative, NPA, (99.7%) percent 
agreements for bacterial identification targets in 
monomicrobial cultures when compared to standard 
microbiology methods and a PPA and NPA for the 
identification of six antimicrobial resistance genes of 
98.3% and 99.9%, respectively. Authors conclude that 
the short assay result time and the valuable clinical 
information that it contains could have the potential to 
improve infection control, select appropriate antibiotic 
therapy earlier and reduce the overall cost of patient 
care.  
Panel-based assays for the identification of 
bloodstream infection pathogens offer several 
advantages. They are simple to perform, require little 
time to set up, and deliver informative results in a short 
time, allowing early optimization of antimicrobial 
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therapy. Limitations of the method include the 
relatively high cost of test performance, especially 
since these tests cannot be used alone, but as an add-on 
to conventional methods for the diagnosis of 
bloodstream infections. In addition, it would be most 
clinically beneficial if these tests could be performed 
24 hours a day, seven days a week; however, that might 
have a negative impact on laboratory resources for 
many clinical microbiology laboratories. 
 
 
Syndromic panel-based testing of respiratory 
infections 
A number of multiplex respiratory panels that 
simultaneously detect more than five pathogens have 
received FDA approval/clearance, and some more are 
available on market as CE-In Vitro Diagnostics (CE-
IVD) assays. These assays differ in the number of 
pathogen targets included, time to result, and the 
number of samples they can process simultaneously. 
They offer sensitive and fast diagnostics compared to 
the conventional methods, such as viral culture, and 
have received clinical evaluation in a number of 
studies.39-41 
The use of multiplex panel-based assay for the 
detection of respiratory pathogens may provide clinical 
benefits, especially when considering particularly 
sensitive populations, such as children or 
immunocompromised patients. Rapid diagnostics of 
respiratory infections caused by viruses reduces the 
unnecessary use of antibiotics, which ultimately results 
in the decrease of antimicrobial resistance and the 
overall cost of hospital treatment. One of the 
limitations of the method includes the inability to 
detect less common causes of respiratory infections. In 
addition, respiratory panel-based assays have a fixed 
combination of detectable microorganisms and cannot 
be tailored to the individual patient. Moreover, further 
clinical studies should investigate the clinical relevance 
of test sensitivity and detection limits for individual 
pathogens in the panel. 
 
 
Syndromic panel-based testing of gastrointestinal 
infections 
Standard microbiology diagnostics of gastrointestinal 
pathogens involves microscopy, culture, individual 
PCR assays and antigen detection methods. In recent 
times, a syndromic approach to the identification of 
gastrointestinal (GI) pathogens has become available 
with multiplex GI panel-based assays. There are 
currently several FDA-approved/cleared highly 
multiplex panel-based assays for the detection of GI 
pathogens. These assays differ in their time-to-result, 
hands-on time and the number of targets included in 
the panel. However, even the most time-consuming 
assays are significantly faster than stool culture (a few 
hours compared to 2-5 days). Several studies 
performed clinical evaluations of multiplex GI assays. 
Buss et al.42 compared the use of a GI multiplex panel 
that detects 22 different enteric pathogens directly from 
stool samples with conventional culture testing and 
other molecular methods. This large study, performed 
on 1554 stool specimens, showed a high specificity and 
a sensitivity of 100% for 12 pathogens, and ≥94.5% for 
additional seven targets. The authors note that, due to 
the low number of positives, the sensitivity was not 
determined for the remaining three pathogens. The 
authors conclude that the assay offers improved 
performance over conventional microbiology methods 
and could aid in the reduction of infection transmission 
by directing appropriate therapy and infection control. 
Spina et al.43 performed a multicenter study of 
community-acquired gastroenteritis comparing the use 
of a GI multiplex panel-based assay with standard 
laboratory procedures for the detection of GI 
pathogens. The authors detected at least one pathogen 
with the panel-based assays in 54.2% of the samples, 
compared to 18.1% found with conventional culture 
methods. Authors conclude with the remark that 
multiplex screening can dramatically improve the time-
to-diagnosis and offer more clinically valuable 
information. Huang et al.44 compared the performance 
of three GI panel-based assays for the detection of six 
common stool pathogens that were included in all off 
the assays. The authors were satisfied with the clinical 
performance of all assays in their patient population, 
and noted their advantage over conventional methods, 
such as the detection of a larger number of pathogens 
and rapid turnaround time.  
Multiplex GI pathogen detection tests have several 
advantages over conventional microbiological testing. 
They enable rapid and accurate diagnosis of a variety 
of enteric pathogens in a single assay setup, enable 
small sample volume testing, increase the possibility of 
detecting coinfection, and show increased analytical 
sensitivity over conventional microbiological methods. 
Although the cost of the testing is high when compared 
to conventional methods, in many cases it is equal or 
even lower than the total cost of testing individual 
microorganisms represented in the multiplex panel. In 
addition, timely and accurate diagnostics provided with 
the use of GI multiplex panel has the potential to 
reduce the overall cost of hospital treatment, which 
favors the inclusion of these tests in the routine work of 
clinical microbiology laboratories. 
 
 
Syndromic panel-based testing for central nervous 
system infections 
Meningitis and encephalitis are very serious conditions 
that are associated with significant morbidity and 
mortality. Bacteria, viruses and fungi can all be 
causative agents of these conditions, with encephalitis 
having a more common viral etiology. First panel-
based syndromic multiplex assay for CNS infections 
(FilmArray meningitis/encephalitis panel) became 
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FDA-cleared in 2015 and targeted 14 causative agents, 
with a turnaround time of approximately one hour 
directly from CSF specimens. Several studies evaluated 
the performance of this assay in clinical settings. Leber 
et al.45 analyzed 1560 prospectively collected CSF 
samples with the multiplex panel assay and compared 
the results with standard culture (for bacterial analytes) 
and PCR (all other analytes). The authors concluded 
that the assay has overall good performance, with high 
sensitivity and specificity, and that it can serve as a 
great aid in the diagnostics of meningitis/encephalitis. 
Two studies evaluated this assay in the pediatric 
clinical setting. Messacar et al.46 analyzed 138 samples 
from children with suspected central nervous system 
infections with the multiplex panel assay and compared 
the results with conventional diagnostics method 
results. Their results suggest that the multiplex panel-
based assay can have comparable diagnostic yield and 
more rapid time-to-diagnosis when compared to 
conventional clinical testing of a suspected CNS 
infection in children. Graf et al.47 performed a 
comparative evaluation of the FilmArray 
meningitis/encephalitis panel assay in 133 samples 
from pediatric population. Their study showed an 
overall agreement of 96.2% between comparator 
methods and the multiplex panel.  
The results of these studies suggest that syndromic 
panel assays for meningitis/encephalitis have a 
comparable diagnostic outcome and allow a shorter 
time to diagnosis than standard microbiological 
techniques. Because a shorter diagnosis time for CNS 
infections may contribute to a timely clinical decision, 
it is presumable that its use will optimize the clinical 
outcome, reduce the use of unnecessary antimicrobial 
and antiviral medications, and shorten the length of 
hospital treatment. A considerable drawback for the 
introduction of syndromic diagnostic tests in routine 
clinical microbiology setting is the overall cost of 
laboratory equipment and reagents. A cost-benefit 
study for each clinical setting would be greatly 
beneficial before considering the introduction of these 




Next generation sequencing and its applications in 
whole genome sequencing and clinical metagenomics 
has great potential for becoming a routinely used 
technology in the clinical microbiology laboratory, for 
it can allow rapid identification and characterization of 
pathogens from a wide variety of samples. Regarding 
several matters, like cost, quality concordance, 
personnel qualifications, etc. it is not yet clear whether 
it could entirely replace routine microbiology 
procedures in the future. It is however apparent that in 
the times to come, more and more laboratories will 
begin to implement WGS according to their specific 
needs. 
Digital PCR has considerable potential for the 
detection of pathogenic microorganisms in the clinical 
microbiology laboratories, due to its superior 
performance characteristics (in the terms of sensitivity, 
accuracy and reliability of experimental data) over 
routinely used qPCR. However, the cost of performing 
digital PCR, that is relatively high when compared with 
qPCR, might make its introduction into the routine 
work of clinical microbiology laboratories somewhat 
challenging.  
Molecular multiplex panel-based assays have provided 
health care professionals with the opportunity to order 
a diagnostic test for the detection of a number of 
microorganisms associated with an infectious 
syndrome, instead of ordering a series of pathogen-
specific individual assays. These assays significantly 
decrease the time-to-diagnosis period, which makes 
them a powerful tool for clinical management, 
including the use of appropriate antimicrobial therapy, 
infection prevention and control.  
Since syndromic panel assays were introduced only 
recently, it is essential to establish clear algorithms and 
guidelines for their use and the interpretation of their 
results. With the further development of the 
technology, and the cost reduction of reagents and 
equipment needed for test performance, one can 
assume that many clinical microbiology laboratories 
will introduce these assays into their routine practice.  
Novel technologies introduced in clinical microbiology 
laboratories will dramatically change the way 
infectious diseases are diagnosed, managed and 
monitored in the years to come. Even though it is 
unlikely that traditional microorganism culturing will 
completely disappear, it is reasonable to presume that 
novel technologies will take an important place in the 
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